Production (Stage)
bluebird bio, Inc.
BLUE
$4.98
-$0.02-0.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 129.31% | 188.30% | 147.15% | 497.77% | 1,149.79% |
| Total Other Revenue | -100.00% | -97.22% | -37.50% | 12.50% | -11.79% |
| Total Revenue | 127.51% | 184.12% | 144.50% | 483.73% | 1,032.60% |
| Cost of Revenue | 40.60% | 166.59% | 145.41% | 158.79% | 140.08% |
| Gross Profit | 444.24% | -38.29% | -113.14% | -115.28% | -105.91% |
| SG&A Expenses | -11.97% | -0.22% | 1.68% | 10.19% | 6.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 100.00% | 100.00% | 100.00% |
| Total Operating Expenses | -17.11% | 28.40% | 219.34% | 328.79% | 221.00% |
| Operating Income | 36.92% | -9.60% | -236.53% | -311.67% | -192.32% |
| Income Before Tax | 33.57% | -13.49% | -367.96% | -515.48% | -237.41% |
| Income Tax Expenses | 234.92% | 155.56% | -376.67% | -167.57% | -207.69% |
| Earnings from Continuing Operations | 33.48% | -13.59% | -367.60% | -515.00% | -236.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.48% | -13.59% | -367.60% | -515.00% | -236.82% |
| EBIT | 36.92% | -9.60% | -236.53% | -311.67% | -192.32% |
| EBITDA | 49.57% | 4.30% | -272.67% | -351.75% | -193.96% |
| EPS Basic | 57.43% | 33.73% | -356.18% | -328.30% | -85.04% |
| Normalized Basic EPS | 59.55% | 34.54% | -353.25% | -312.58% | -95.68% |
| EPS Diluted | 57.48% | 33.95% | -346.57% | -320.77% | -83.88% |
| Normalized Diluted EPS | 59.55% | 34.57% | -352.46% | -312.07% | -95.57% |
| Average Basic Shares Outstanding | 46.75% | 76.48% | 72.28% | 62.42% | 54.17% |
| Average Diluted Shares Outstanding | 46.75% | 76.33% | 72.12% | 62.25% | 54.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |